The scene has been set for research into gene misexpression across different tissues, to understand the part it plays in a range of diseases and search for new drug targets, following publication of the first comprehensive survey of where genes are active when they are expected to be switched off. Read More

Alkira Bio, a new spinout from Australia’s Florey Institute of Neuroscience and Mental Health has emerged from stealth mode thanks to seed funding from Curie.bio. Although the amount of funding is not disclosed, Curie.bio typically invests $5 million to $10 million in a founder company and then co-pilots the drug discovery program, deploying drug development experts to its portfolio companies to help navigate decision making as part of the deal, Florey researcher turned Alkira Bio CEO Daniel Scott told BioWorld. Read More

Parvus Therapeutics Inc.'s PVT-201 has received orphan drug status from the U.S. FDA for the treatment of primary biliary cholangitis (PBC), an autoimmune disease of the liver. Read More

Researchers from University of Tsukuba published data from a study designed to identify novel biomarkers for predicting treatment responses to nivolumab plus ipilimumab combination therapy. Read More

Guangdong Newopp Biopharmaceuticals Co. Ltd. has identified macrocyclic derivatives acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer. Read More

Researchers from Northeast Normal University in Changchun demonstrated that compound AW-01178 reversed the abnormal regulation of E-cadherin by inhibiting the class I HDAC enzyme. Read More

From no hope to viable treatments, BioWorld  is there to cover the breakthroughs in medicine. Listen to Randy Osborne explain why the BioWorld  team is ‘always on the lookout for what's next.’ Read More

The US FDA has cleared an IND application for COM-503, high affinity anti-IL-18 binding protein antibody, in solid tumors. Read More

DeepSA, an edit-based generative framework that utilizes deep simulated annealing (SA), was used to develop novel local anesthetics with multiple activities. Researchers from Sichuan University applied DeepSA to generate over 400 analogs of the local anesthetic articaine. Read More

Jiangsu Mingsheng Jutai Biotechnology Co. Ltd. has patented β-catenin (CTNNB1)/BCL9 interaction inhibitors reported to be useful for the treatment of cancer and fibrosis. Read More

Haisco Pharmaceutical Group Co. Ltd. has discovered sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain. Read More

GSK plc and Flagship Pioneering Inc. have entered a collaboration to discover and develop a portfolio of therapeutics and vaccines for respiratory and immunology indications. Read More

Blueprint Medicines Corp. has synthesized Cyclin-dependent kinase 2 (CDK2) inhibitors reported to be useful for the treatment of cancer. Read More

Tibet Haisco Pharmaceutical Co. Ltd. has divulged myosin-2 (MYH2) inhibitors reported to be useful for the treatment of muscular dystrophy. Read More

Scientists at Boehringer Ingelheim GmbH have made the ketohexokinase (KHK) inhibitor BI-9787 freely available as a tool compound via the company’s Opnme program. Read More